CA24463V1013
© EQS Newswire
06.06.2024
DTC
LISTED
CSE
DEFENCE VERÖFFENTLICHT SEINE PEER-REVIEW-STUDIE MIT PRÄKLINISCHEN DATEN ÜBER ACCUTOX ALS ANTIKREBSMOLEKÜL IM RENOMMIERTEN ‚JOURNAL OF TRANSLATIONAL MEDICINE‘
News Preview
_________________________________________________________________
CSE: DTC Börse Frankfurt: DTC OTCQB: DTCFF PRESSEMITTEILUNG
DEFENCE VERÖFFENTLICHT SEINE PEER-REVIEW-STUDIE MIT PRÄKLINISCHEN DATEN ÜBER ACCUTOX ALS ANTIKREBSMOLEKÜL IM RENOMMIERTEN ‚JOURNAL OF TRANSLATIONAL MEDICINE‘
Vancouver, British Columbia, Kanada, den 6. Juni ......
Themefolio
Profiler
Peergroup
© Newsfile
06.06.2024
DTC
LISTED
CSE
Defence's AccuTOX Published in the Prestigious Journal of Translational Medicine Its Peer Study with Preclinical Data on AccuTOX as an Anti-Cancer Molecule
News Preview
Vancouver, British Columbia--(Newsfile Corp. - June 6, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is please to announce the publication of a peer-reviewed study on the anticancer...
Themefolio
Profiler
Peergroup
© EQS Newswire
06.06.2024
DTC
LISTED
CSE
DEFENCE’S ACCUTOX PUBLISHED IN THE PRESTIGIOUS JOURNAL OF TRANSLATIONAL MEDICINE ITS PEER STUDY WITH PRECLINICAL DATA ON ACCUTOX AS AN ANTI-CANCER MOLECULE
News Preview
_________________________________________________________________
CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE
DEFENCE’S ACCUTOX PUBLISHED IN THE PRESTIGIOUS JOURNAL OF TRANSLATIONAL MEDICINE ITS PEER STUDY WITH PRECLINICAL DATA ON ACCUTOX AS AN ANTI-CANCER MOLECULE
Vancouver, BC, Canada, June 6th, 2024 - Defence Therapeutics Inc. (......
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© EQS Newswire
06.06.2024
DTC
LISTED
CSE
DEFENCE’S ACCUTOX PUBLISHED IN THE PRESTIGIOUS JOURNAL OF TRANSLATIONAL MEDICINE ITS PEER STUDY WITH PRECLINICAL DATA ON ACCUTOX AS AN ANTI-CANCER MOLECULE
News Preview
_________________________________________________________________
CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE
DEFENCE’S ACCUTOX PUBLISHED IN THE PRESTIGIOUS JOURNAL OF TRANSLATIONAL MEDICINE ITS PEER STUDY WITH PRECLINICAL DATA ON ACCUTOX AS AN ANTI-CANCER MOLECULE
Vancouver, BC, Canada, June 6th, 2024 - Defence Therapeutics Inc. (......
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Newsfile
14.05.2024
DTC
LISTED
CSE
Defence Therapeutics Strengthens and Expands Global Patent Protection on Key Technologies
News Preview
Vancouver, British Columbia--(Newsfile Corp. - May 14, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce the issuance of several new patents, as well as new allowanc...
Themefolio
Profiler
Peergroup
© EQS Newswire
14.05.2024
DTC
LISTED
CSE
DEFENCE THERAPEUTICS STRENGTHENS AND EXPANDS GLOBAL PATENT PROTECTION ON KEY TECHNOLOGIES
News Preview
CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE
DEFENCE THERAPEUTICS STRENGTHENS AND EXPANDS GLOBAL PATENT PROTECTION ON KEY TECHNOLOGIES
Vancouver, BC, Canada, May 14, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a Canadian biopharmaceutical company developing novel immune-oncology ......
Themefolio
Profiler
Peergroup
© EQS Newswire
14.05.2024
DTC
LISTED
CSE
DEFENCE THERAPEUTICS VERSTÄRKT UND ERWEITERT DEN WELTWEITEN PATENTSCHUTZ FÜR SCHLÜSSELTECHNOLOGIEN
News Preview
CSE: DTC Börse Frankfurt: DTC USOTC:DTCFF PRESSEMITTEILUNG
DEFENCE THERAPEUTICS VERSTÄRKT UND ERWEITERT DEN WELTWEITEN PATENTSCHUTZ FÜR SCHLÜSSELTECHNOLOGIEN
Vancouver, British Columbia, Kanada, den 14. Mai 2024 - Defence Therapeutics Inc. („Defence“ oder das „Unternehmen“), (CSE: DTC, OTCQB: DTCFF, Börse Frankfurt: DTC), ein kanadische......
Themefolio
Profiler
Peergroup
© EQS Newswire
02.05.2024
DTC
LISTED
CSE
ERFOLGREICHER TEST ZUR BEKÄMPFUNG VON PANKREASKREBS MIT DEM ARM-002-IMPFSTOFF VON DEFENCE
News Preview
_________________________________________________________________
CSE: DTC Börse Frankfurt: DTC USOTC:DTCFF PRESSEMITTEILUNG
PANKREASKREBS: ERFOLGREICHER TEST ZUR BEKÄMPFUNG VON PANKREASKREBS MIT DEM ARM-002-IMPFSTOFF VON DEFENCE
Vancouver, British Columbia, Kanada, den 1. Mai 2024 - Defence Therapeutics Inc. („Defence“ oder das „Unter......
Themefolio
Profiler
Peergroup
© EQS Newswire
02.05.2024
DTC
LISTED
CSE
ERFOLGREICHER TEST ZUR BEKÄMPFUNG VON PANKREASKREBS MIT DEM ARM-002-IMPFSTOFF VON DEFENCE
News Preview
_________________________________________________________________
CSE: DTC Börse Frankfurt: DTC USOTC:DTCFF PRESSEMITTEILUNG
PANKREASKREBS: ERFOLGREICHER TEST ZUR BEKÄMPFUNG VON PANKREASKREBS MIT DEM ARM-002-IMPFSTOFF VON DEFENCE
Vancouver, British Columbia, Kanada, den 1. Mai 2024 - Defence Therapeutics Inc. („Defence“ oder das „Unter......
Themefolio
Profiler
Peergroup
© EQS Newswire
02.05.2024
DTC
LISTED
CSE
SUCCESFUL TRIAL AGAINST PANCREATIC CANCER WITH DEFENCE’S ARM-002 ANTI-CANCER VACCINE
News Preview
_________________________________________________________________
CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE
PANCREACTIC CANCER: SUCCESFUL TRIAL AGAINST PANCREATIC CANCER WITH DEFENCE’S ARM-002 ANTI-CANCER VACCINE
Vancouver, BC, Canada, May 1st, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: D......
Themefolio
Profiler
Peergroup
© Newsfile
01.05.2024
DTC
LISTED
CSE
Pancreatic Cancer: Successful Trial Against Pancreatic Cancer with Defence Therapeutics' ARM-002 Anti-Cancer Vaccine
News Preview
Vancouver, British Columbia--(Newsfile Corp. - May 1, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce the successful completion of a pre-clinical vaccination...
Themefolio
Profiler
Peergroup
© EQS Newswire
23.04.2024
DTC
LISTED
CSE
DER ACCUTOX ARM-002-IMPFSTOFF ZUR KREBSBEKÄMPFUNG FÜHRT ZU EINER HOCHWIRKSAMEN ANTIGENPRÄSENTATION
News Preview
Vancouver, British Columbia, Kanada, den 23. April 2024 - Defence Therapeutics Inc. („Defence“ oder das „Unternehmen“), (CSE: DTC, OTCQB: DTCFF, Börse Frankfurt: DTC), ein kanadisches Biotech-Unternehmen, das neuartige immunonkologische Therapeutika und Technologien zur Arzneimittelverabreichung entwickelt, freut sich bekanntzugeben, dass sein ARMT......
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Newsfile
23.04.2024
DTC
LISTED
CSE
Defence's AccuTOX Anti-Cancer ARM-002 Vaccine Exhibits Potent Antigen Presentation
News Preview
Vancouver, British Columbia--(Newsfile Corp. - April 23, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce that its second-generation ARMTM anti-cancer vaccine u...
Themefolio
Profiler
Peergroup
© EQS Newswire
23.04.2024
DTC
LISTED
CSE
DEFENCE’S ACCUTOX ANTI-CANCER ARM-002 VACCINE EXHIBITS POTENT ANTIGEN PRESENTATION
News Preview
Vancouver, BC, Canada, April 23rd, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce that its second-generation ARMTM anti-cancer vaccine using AccuTOX®, called AR......
Themefolio
Profiler
Peergroup
© Newsfile
17.04.2024
DTC
LISTED
CSE
Defence Therapeutics Signs with German Based FMS Consult GmbH for Financing Strategy to Support Defence Pipeline Growth
News Preview
Vancouver, British Columbia--(Newsfile Corp. - April 17, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce that FMS Consult GmbH ("FMS"), a European corporate fi...
Themefolio
Profiler
Peergroup
© EQS Newswire
17.04.2024
DTC
LISTED
CSE
DEFENCE THERAPEUTICS UNTERZEICHNET MIT DER DEUTSCHEN FMS CONSULT GMBH EINE FINANZIERUNGSSTRATEGIE ZUR UNTERSTÜTZUNG DES WACHSTUMS DES DEFENCE-PORTFOLIOS
News Preview
CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE
Vancouver, BC, Kanada, 17. April 2024 - Defence Therapeutics Inc. (“Defence” oder das („Unternehmen”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), ein kanadisches biopharmazeutisches Unternehmen, das neuartige Immunonkologie-Therapeutika und Arzneimittelabgabetechnologien entwickelt, freut sich bekannt z......
Themefolio
Profiler
Peergroup
© EQS Newswire
17.04.2024
DTC
LISTED
CSE
DEFENCE THERAPEUTICS SIGNS WITH GERMAN BASED FMS CONSULT GMBH FOR FINANCING STRATEGY TO SUPPORT DEFENCE PIPELINE GROWTH
News Preview
CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE
Vancouver, BC, Canada, April 17th, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce that FMS Consult GmbH (“F......
Themefolio
Profiler
Peergroup
© Newsfile
06.04.2024
DTC
LISTED
CSE
Defence Therapeutics Announces Warrant Terms Amendment
News Preview
Vancouver, British Columbia--(Newsfile Corp. - April 5, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology companies working in the field of immune-oncology, announces an amendment to the terms of 1,497,780 Class A Common share purchase warrants (the "Warran...
Themefolio
Profiler
Peergroup
© EQS Newswire
26.03.2024
DTC
LISTED
CSE
ERFOLGE VON DEFENCE BEI SEINEM ACCUTOX®-ARM(TM)-VAKZIN ZUR KREBSBEKÄMPFUNG FÜHREN ZUR ENTWICKLUNG EINES WIRKUNGSVOLLEN ARM-002(TM)-KREBSIMPFSTOFFS DER ZWEITEN GENERATION
News Preview
CSE: DTC Börse Frankfurt: DTC OTCQB: DTCFF PRESSEMITTEILUNG
ERFOLGE VON DEFENCE BEI SEINEM ACCUTOX®-ARMTM-VAKZIN ZUR KREBSBEKÄMPFUNG FÜHREN ZUR ENTWICKLUNG EINES WIRKUNGSVOLLEN ARM-002TM-KREBSIMPFSTOFFS DER ZWEITEN GENERATION
Vancouver, British Columbia, Kanada, den 26. März 2024 – Defence Therapeutics Inc. („Defence“ oder das „Untern......
Themefolio
Profiler
Peergroup
© Newsfile
26.03.2024
DTC
LISTED
CSE
Defence's Successful Results on Its AccuTOX Anti-Cancer ARM Vaccine Creates a Potent Second-Generation Anti-Cancer ARM-002 Vaccine
News Preview
Vancouver, British Columbia--(Newsfile Corp. - March 26, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biotechnology company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce the successful testing of a second-generation anti-cancer...
Themefolio
Profiler
Peergroup
© EQS Newswire
26.03.2024
DTC
LISTED
CSE
DEFENCE’S SUCCESSFUL RESULTS ON ITS ACCUTOX® ANTI-CANCER ARMTM VACCINE CREATES A POTENT SECOND-GENERATION ANTI-CANCER ARM-002TM VACCINE
News Preview
_________________________________________________________________
CSE: DTC FSE: DTC OTCQB: DTCFF PRESS RELEASE
DEFENCE’S SUCCESSFUL RESULTS ON ITS ACCUTOX® ANTI-CANCER ARMTM VACCINE CREATES A POTENT SECOND-GENERATION ANTI-CANCER ARM-002TM VACCINE
Vancouver, BC, Canada, March 26th, 2024 - Defence Therapeutics Inc. (“Defence” or ......
Themefolio
Profiler
Peergroup
© Newsfile
22.03.2024
DTC
LISTED
CSE
Defence Completes 2nd Tranche of Financing
News Preview
Vancouver, British Columbia--(Newsfile Corp. - March 22, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), one of the leading Canadian biotechnology companies working in the field of immune-oncology, announces the closing of the 2nd tranche of its previously announced non-brokered private placemen...
Themefolio
Profiler
Peergroup
© EQS Newswire
04.03.2024
DTC
LISTED
CSE
DEFENCE THERAPEUTICS WURDE EIN UMFASSENDES PATENT GEWÄHRT, DAS DIE BAHNBRECHENDE ACCUTOX®-TECHNOLOGIE ZUR KREBSBEKÄMPFUNG ABDECKT
News Preview
________________________________________________________________
CSE: DTC Börse Frankfurt: DTC USOTC: DTCFF PRESSEMITTEILUNG
DEFENCE THERAPEUTICS WURDE EIN UMFASSENDES PATENT GEWÄHRT, DAS DIE BAHNBRECHENDE ACCUTOX®-TECHNOLOGIE ZUR KREBSBEKÄMPFUNG ABDECKT
Vancouver, British Columbia (Kanada), den 4. März 2024 – Defence Therapeutics Inc. (......
Themefolio
Profiler
Peergroup
© Newsfile
04.03.2024
DTC
LISTED
CSE
Defence Therapeutics Awarded Broad U.S. Patent Covering Its Pioneering Cancer-Killing AccuTOX(R) Technology
News Preview
Vancouver, British Columbia--(Newsfile Corp. - March 4, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce the granting of US patent no. 11,890,350 ('350) by the...
Themefolio
Profiler
Peergroup
© EQS Newswire
04.03.2024
DTC
LISTED
CSE
DEFENCE THERAPEUTICS AWARDED BROAD U.S. PATENT COVERING ITS PIONEERING CANCER-KILLING ACCUTOX® TECHNOLOGY
News Preview
_________________________________________________________________
CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE
DEFENCE THERAPEUTICS AWARDED BROAD U.S. PATENT COVERING ITS PIONEERING CANCER-KILLING ACCUTOX® TECHNOLOGY
Vancouver, BC, Canada, March 4th, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceu......
Themefolio
Profiler
Peergroup
© Newsfile
01.03.2024
DTC
LISTED
CSE
Defence Announces Peer-Reviewed Publication on Accum-E7 Anti-Cancer Vaccine in Cancer Science Journal and Financing Update
News Preview
Vancouver, British Columbia--(Newsfile Corp. - February 29, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology companies working in the field of immune-oncology, is pleased to announce the publication of a peer-reviewed study on the anticancer properties of...
Themefolio
Profiler
Peergroup
© Newsfile
31.01.2024
DTC
LISTED
CSE
Defence Therapeutics Completes 1st Tranche of Financing
News Preview
Vancouver, British Columbia--(Newsfile Corp. - January 30, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology companies working in the field of immune-oncology, announces the closing of the 1st tranche of its previously announced non-brokered private pl...
Themefolio
Profiler
Peergroup
© Newsfile
20.01.2024
DTC
LISTED
CSE
Defence Financing
News Preview
Vancouver, British Columbia--(Newsfile Corp. - January 19, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology companies working in the field of immune-oncology announces, further to its news release on January 12, 2024, an amendment on the financing. Th...
Themefolio
Profiler
Peergroup
© Newsfile
13.01.2024
DTC
LISTED
CSE
Defence Begins Trading on the OTCQB and Arranges Financing
News Preview
Vancouver, British Columbia--(Newsfile Corp. - January 12, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), one of the leading Canadian biotechnology companies working in the field of immune-oncology is pleased to announce that it arranges a financing, and its common shares have been upgraded to...
Themefolio
Profiler
Peergroup
© EQS Newswire
10.01.2024
DTC
LISTED
CSE
ACCUTOX® VON DEFENCE HEMMT WACHSTUM VON LUNGENKREBS
News Preview
_________________________________________________________________
CSE: DTC Börse Frankfurt: DTC USOTC: DTCFF PRESSEMITTEILUNG
ACCUTOX® VON DEFENCE HEMMT WACHSTUM VON LUNGENKREBS
Vancouver, British Columbia, Kanada, den 10. Januar 2024 – Defence Therapeutics Inc. („Defence“ oder das „Unternehmen“), (CSE: DTC, OTCQB: DTCFF, Börse Frankfur......
Themefolio
Profiler
Peergroup
© Newsfile
10.01.2024
DTC
LISTED
CSE
Defence's AccuTOX(R) Impairs Lung Cancer Growth
News Preview
Vancouver, British Columbia--(Newsfile Corp. - January 10, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), one of the leading Canadian biotechnology companies working in the field of immune-oncology is pleased to announce that it successfully tested a new formulation of its ACCUM-002TM Dime...
Themefolio
Profiler
Peergroup
© EQS Newswire
10.01.2024
DTC
LISTED
CSE
DEFENCE’S ACCUTOX® IMPAIRS LUNG CANCER GROWTH
News Preview
_________________________________________________________________
CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE
DEFENCE’S ACCUTOX® IMPAIRS LUNG CANCER GROWTH
Vancouver, BC, Canada, January 10th, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), one of the leading Canadian biotechno......
Themefolio
Profiler
Peergroup
© Newsfile
12.12.2023
DTC
LISTED
CSE
RETRANSMISSION: Defence Receives FDA Approval for Phase I Clinical Trial Targeting Solid Cancer Tumors with AccuTOX(R)
News Preview
Vancouver, British Columbia--(Newsfile Corp. - December 12, 2023) - Defence Therapeutics Inc. (CSE: DTC) (OTC Pink: DTCFF) (FSE: DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology companies working in the field of immune-oncology is pleased to announce that the U.S. FDA issued a "Study May Proceed", this clears its Investi...
Themefolio
Profiler
Peergroup
© Newsfile
11.12.2023
DTC
LISTED
CSE
Defence Receives FDA Approval for Phase I Clinical Trial Targeting Solid Cancer Tumors with AccuTOX(R)
News Preview
Vancouver, British Columbia--(Newsfile Corp. - December 11, 2023) - Defence Therapeutics Inc. (CSE: DTC) (OTC Pink: DTCFF) (FSE: DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology companies working in the field of immune-oncology is pleased to announce that the U.S. FDA has cleared today "Study May Proceed" its Investigati...
Themefolio
Profiler
Peergroup
© Newsfile
14.11.2023
DTC
LISTED
CSE
Defence's Successful Submission of an Investigational New Drug (IND) Application for AccuTOX(R) as an Injectable Anticancer Treatment for Solid Tumors
News Preview
Vancouver, British Columbia--(Newsfile Corp. - November 14, 2023) - Defence Therapeutics Inc. (CSE: DTC) (OTC Pink: DTCFF) (FSE: DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology companies working in the field of immune-oncology is pleased to announce that it has successfully submitted on November 9, 2023 an Investigatio...
Themefolio
Profiler
Peergroup
© Newsfile
07.11.2023
DTC
LISTED
CSE
Defence Therapeutics Key Platform Patent Accepted Broadly Covering Vaccine Technology
News Preview
Vancouver, British Columbia--(Newsfile Corp. - November 7, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing cutting-edge vaccines, therapeutics, and drug delivery technologies against cancer and other diseases, is pleased to announce th...
Themefolio
Profiler
Peergroup
© Newsfile
25.10.2023
DTC
LISTED
CSE
Defence's AccuTOX(R) And Antigen Cross-Presentation: Discovery Leads Towards the Development of a Groundbreaking Platform
News Preview
Vancouver, British Columbia--(Newsfile Corp. - October 25, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a leading Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the discovery of...
Themefolio
Profiler
Peergroup
© Newsfile
18.10.2023
DTC
LISTED
CSE
Defence's Novel Accutox(TM) Continues to Surprise on Results Against Cancer
News Preview
Vancouver, British Columbia--(Newsfile Corp. - October 18, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that the excitement around AccuTOXTM...
Themefolio
Profiler
Peergroup
© Newsfile
17.10.2023
DTC
LISTED
CSE
Defence's Delivery of Encapsulated AccuTOX(TM)-Chitosan Nanoparticles Triggers Complete Tumor Regression in Animals with Pre-Established Solid Lymphoma
News Preview
Vancouver, British Columbia--(Newsfile Corp. - October 17, 2023) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that systemic administration of novel AccuTOXTM-chitosan encapsul...
Themefolio
Profiler
Peergroup
© Newsfile
10.10.2023
DTC
LISTED
CSE
Defence Announces Peer-reviewed Publication of Its Preclinical Data on Accum(R) as an Anti-Cancer Molecule in the Journal of Cancer Science
News Preview
Vancouver, British Columbia--(Newsfile Corp. - October 10, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a biotechnology company developing various products for the immune-oncology vaccines and drug delivery technologies, is pleased to announce the publication of a peer-reviewed study on the...
Themefolio
Profiler
Peergroup
© Newsfile
07.10.2023
DTC
LISTED
CSE
Defence to Present Three of Its Leading Products at the Upcoming Festival of Biologics in Basel, Switzerland
News Preview
Vancouver, British Columbia--(Newsfile Corp. - October 6, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce its participation to the upcoming Fes...
Themefolio
Profiler
Peergroup
© Newsfile
25.09.2023
DTC
LISTED
CSE
Defence's Accum(R)-mRNA Lipid Nanoparticles Elicit Antibody Response 2X Stronger than Standard mRNA Vaccines
News Preview
Vancouver, British Columbia--(Newsfile Corp. - September 25, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that its encapsulation strategy us...
Themefolio
Profiler
Peergroup
© Newsfile
22.09.2023
DTC
LISTED
CSE
Defence to Collaborate with Native Ads for Marketing Campaign
News Preview
Vancouver, British Columbia--(Newsfile Corp. - September 22, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce it has entered into a servic...
Themefolio
Profiler
Peergroup
© Newsfile
12.09.2023
DTC
LISTED
CSE
Defence's Broad and Versatile Accum(R) Technology Platform Focus on Cancer Therapeutics
News Preview
Vancouver, British Columbia--(Newsfile Corp. - September 12, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), one of the leading Canadian biotechnology companies, is pleased to announce its continuation to bringing innovative strategies aimed at targeting various indications related to immune-o...
Themefolio
Profiler
Peergroup
© Newsfile
05.09.2023
DTC
LISTED
CSE
Defence's Innovative Therapeutics Featured on Viewpoint with Dennis Quaid
News Preview
Vancouver, British Columbia--(Newsfile Corp. - September 5, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company") a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies is pleased to announce that Viewpoint, the educational television show distri...
Themefolio
Profiler
Peergroup
© Newsfile
18.07.2023
DTC
LISTED
CSE
Defence Successfully Completes the First Milestone of Its Collaboration Agreement with Orano
News Preview
Vancouver, British Columbia--(Newsfile Corp. - July 18, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company") is pleased to announce that it has successfully reached the first milestone established in the Collaboration Agreement with Orano Support SAS on behalf of Orano SA ("Orano"), a world-renowned...
Themefolio
Profiler
Peergroup
© Newsfile
05.07.2023
DTC
LISTED
CSE
RETRANSMISSION: Defence and Viewpoint with Dennis Quaid Join Forces to Explore Breakthroughs in Biotechnology
News Preview
Vancouver, British Columbia--(Newsfile Corp. - July 5, 2023) - Defence Therapeutics Inc. ("Defence" or the "Company") a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies is pleased to announce its collaboration with Viewpoint with Dennis Quaid. This exciting partnership aims to explore break...
Themefolio
Profiler
Peergroup
© Newsfile
04.07.2023
DTC
LISTED
CSE
Defence and Viewpoint with Dennis Quaid Join Forces to Explore Breakthroughs in Biotechnology
News Preview
Vancouver, British Columbia--(Newsfile Corp. - July 4, 2023) - Defence Therapeutics Inc. ("Defence" or the "Company") a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies is pleased to announce its collaboration with Viewpoint with Dennis Quaid. This exciting partnership aims...
Themefolio
Profiler
Peergroup
© Newsfile
28.06.2023
DTC
LISTED
CSE
Defence Patent Portfolio at the Forefront of Success
News Preview
Vancouver, British Columbia--(Newsfile Corp. - June 28, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company") is a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies. Sitting at the core of its innovative technologies is the proprietary Accum&#...
Themefolio
Profiler
Peergroup
© Newsfile
20.06.2023
DTC
LISTED
CSE
Defence's Proprietary Accum(TM) Technology for Delivery of CRISPR/Cas Genome-Editing Complexes Patent Application Published
News Preview
Vancouver, British Columbia--(Newsfile Corp. - June 20, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce the publication of its new international (PCT) patent ap...
Themefolio
Profiler
Peergroup
© Newsfile
16.06.2023
DTC
LISTED
CSE
Defence Manufacturing of AccuTox(TM) CGMP Final Drug Product Optimization for Its Phase I Clinical Trial at City of Hope
News Preview
Vancouver, British Columbia--(Newsfile Corp. - June 16, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce that it reached the final stages of its...
Themefolio
Profiler
Peergroup
© Newsfile
06.06.2023
DTC
LISTED
CSE
Defence Begins Testing Its Arm Vaccine Against Pancreatic Cancer
News Preview
Vancouver, British Columbia--(Newsfile Corp. - June 6, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce that it mandated Transbiotech Biote...
Themefolio
Profiler
Peergroup
© Newsfile
26.05.2023
DTC
LISTED
CSE
Defence Announces Additional and Final Exercises of Warrants for Gross Proceeds of Over $2.3 Million
News Preview
Vancouver, British Columbia--(Newsfile Corp. - May 26, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that, in addition to the previously anno...
Themefolio
Profiler
Peergroup
© Newsfile
24.05.2023
DTC
LISTED
CSE
Breakthrough Results: Defence's Arm Vaccine Cured 100% of Animals with Pre-Established Lymphoma
News Preview
Vancouver, British Columbia--(Newsfile Corp. - May 24, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce the successful completion of a pre-clinic...
Themefolio
Profiler
Peergroup
© Newsfile
10.05.2023
DTC
LISTED
CSE
BTV Investor Alert - Defence Therapeutics: Developing Immune-Related Therapies for Cancer Treatment
News Preview
Vancouver, British Columbia--(Newsfile Corp. - May 10, 2023) - Defence Therapeutics Inc. (CSE: DTC) (OTC Pink: DTCFF) - Defence Therapeutics is a Canadian biotech company that develops immune-related cancer therapies with proprietary technology. With three clinical trials scheduled by year-end, the company offers growth potential for investors. Def...
Themefolio
Profiler
Peergroup
© Newsfile
02.05.2023
DTC
LISTED
CSE
Defence's Successful AccuTOX(TM) Pre-Clinical Efficacy Study Complete Ready For Phase I IND Filing
News Preview
Vancouver, British Columbia--(Newsfile Corp. - May 2, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce the successful completion of all required...
Themefolio
Profiler
Peergroup
© Newsfile
27.04.2023
DTC
LISTED
CSE
USPTO Grants Trademark Registration for Defence Therapeutics(R)
News Preview
Vancouver, British Columbia--(Newsfile Corp. - April 27, 2023) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that the United States Patent and Trademark Office (USPTO) has granted registration...
Themefolio
Profiler
Peergroup
© Newsfile
24.04.2023
DTC
LISTED
CSE
Defence Granted US Patent with Broad Coverage on Accum(TM)-based Vaccine Enhancer Platform Technology
News Preview
Vancouver, British Columbia--(Newsfile Corp. - April 24, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies including Antibody Drug Conjugates ("ADCs"), is pleased to announce the is...
Themefolio
Profiler
Peergroup
© Newsfile
17.04.2023
DTC
LISTED
CSE
Defence's Novel Accum(TM)-mRNA Vaccine Now Administered for Testing on Cancer
News Preview
Vancouver, British Columbia--(Newsfile Corp. - April 17, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that it commenced comparing the therap...
Themefolio
Profiler
Peergroup
© Newsfile
11.04.2023
DTC
LISTED
CSE
RETRANSMISSION: Defence Breakthrough: Successfully Engineered Accum(TM)-mRNA Vaccine Creating a New Vaccine Platform. The in vivo Accum(TM)-mRNA Cancer Vaccine Program Begins
News Preview
Vancouver, British Columbia--(Newsfile Corp. - April 11, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that it successfully established a st...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
